These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 12602079)

  • 61. The role of economic appraisal in Denmark.
    Alban A
    Soc Sci Med; 1994 Jun; 38(12):1647-52. PubMed ID: 8047923
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Hierarchical commensurate and power prior models for adaptive incorporation of historical information in clinical trials.
    Hobbs BP; Carlin BP; Mandrekar SJ; Sargent DJ
    Biometrics; 2011 Sep; 67(3):1047-56. PubMed ID: 21361892
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
    Dong G; Shih WJ; Moore D; Quan H; Marcella S
    Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals.
    Bryan S; Williams I; McIver S
    Health Econ; 2007 Feb; 16(2):179-93. PubMed ID: 16960851
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Bayesian cost-effectiveness analysis from clinical trial data.
    O'Hagan A; Stevens JW; Montmartin J
    Stat Med; 2001 Mar; 20(5):733-53. PubMed ID: 11241573
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Addressing prior-data conflict with empirical meta-analytic-predictive priors in clinical studies with historical information.
    Li JX; Chen WC; Scott JA
    J Biopharm Stat; 2016; 26(6):1056-1066. PubMed ID: 27541990
    [TBL] [Abstract][Full Text] [Related]  

  • 67. An iterative Bayesian approach to health technology assessment: application to a policy of preoperative optimization for patients undergoing major elective surgery.
    Fenwick E; Palmer S; Claxton K; Sculpher M; Abrams K; Sutton A
    Med Decis Making; 2006; 26(5):480-96. PubMed ID: 16997926
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Technology assessment in Catalonia: integrating economic appraisal.
    Granados A; Borràs JM
    Soc Sci Med; 1994 Jun; 38(12):1643-6. PubMed ID: 8047922
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Policy relevance of Bayesian statistics overestimated?
    van der Wilt GJ; Rovers M; Straatman H; van der Bij S; van den Broek P; Zielhuis G
    Int J Technol Assess Health Care; 2004; 20(4):488-92. PubMed ID: 15609800
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The Impact of Decision Makers' Constraints on the Outcome of Value of Information Analysis.
    Koffijberg H; Knies S; Janssen MP
    Value Health; 2018 Feb; 21(2):203-209. PubMed ID: 29477402
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Assessing the costs of healthcare technologies in clinical trials.
    Johnston K; Buxton MJ; Jones DR; Fitzpatrick R
    Health Technol Assess; 1999; 3(6):1-76. PubMed ID: 10350450
    [No Abstract]   [Full Text] [Related]  

  • 72. Globally optimal trial design for local decision making.
    Eckermann S; Willan AR
    Health Econ; 2009 Feb; 18(2):203-16. PubMed ID: 18435429
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Bayeswatch: an overview of Bayesian statistics.
    Austin PC; Brunner LJ; Hux JE
    J Eval Clin Pract; 2002 May; 8(2):277-86. PubMed ID: 12060417
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Bayesian methods in meta-analysis and evidence synthesis.
    Sutton AJ; Abrams KR
    Stat Methods Med Res; 2001 Aug; 10(4):277-303. PubMed ID: 11491414
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cost-effectiveness acceptability curves--caveats quantified.
    Jakubczyk M; Kamiński B
    Health Econ; 2010 Aug; 19(8):955-63. PubMed ID: 19688780
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The use of exploratory analyses within the National Institute for Health and Care Excellence single technology appraisal process: an evaluation and qualitative analysis.
    Kaltenthaler E; Carroll C; Hill-McManus D; Scope A; Holmes M; Rice S; Rose M; Tappenden P; Woolacott N
    Health Technol Assess; 2016 Apr; 20(26):1-48. PubMed ID: 27049841
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Aggregate Distributional Cost-Effectiveness Analysis of Health Technologies.
    Love-Koh J; Cookson R; Gutacker N; Patton T; Griffin S
    Value Health; 2019 May; 22(5):518-526. PubMed ID: 31104729
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Incorporating model uncertainty in cost-effectiveness analysis: a Bayesian model averaging approach.
    Negrín MA; Vázquez-Polo FJ
    J Health Econ; 2008 Sep; 27(5):1250-9. PubMed ID: 18490067
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A full Bayesian model to handle structural ones and missingness in economic evaluations from individual-level data.
    Gabrio A; Mason AJ; Baio G
    Stat Med; 2019 Apr; 38(8):1399-1420. PubMed ID: 30565727
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Use of external evidence for design and Bayesian analysis of clinical trials: a qualitative study of trialists' views.
    Clayton GL; Elliott D; Higgins JPT; Jones HE
    Trials; 2021 Nov; 22(1):789. PubMed ID: 34749778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.